An increased binding potential of [11C]SCH442416 was observed in the striatum of Parkinson’s patients with levodopa-induced dyskinesias (LIDs), providing evidence that A2AR is a potential pharmacological target for the management of LIDs [75]. Here, ADORA2A is linked to Parkinson disease.